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tobacco products in next ten years. The purpose of this bill is to protect 
the Korean people from the harmful effects of tobacco use by banning 
the manufacture and sale of tobacco products in the Republic of Korea. 
According to the proposed legislation, no person shall commit acts fall-
ing under any of the following subparagraphs: 
1. An act of manufacturing tobacco products or an act of manufactur-
ing, importing, selling, brokering the sale of, having or holding raw 
material that is used in the production of tobacco products 
2. An act of importing or exporting tobacco products or an act of hav-
ing or holding them for the purposes of importation or exportation 
3. An act of selling or brokering the sale of tobacco products or an act 
of having or holding them in order to sell or broker the sale of them 
4. An act of providing another person with any lands, facilities, ma-
chineries or equipments, funds, transports in order to help him or her 
to commit any offence speciﬁed in the above three subparagraphs of 
this article. 
It is proposed that this Act shall enter into force ten years after the date 
of its promulgation to allow an adequate period of preparation, com-
pensation, decreasing smoking rate, identiﬁcation of substitute sources 
of governmental and provincial tax, and alternative employment for 
tobacco growers, manufacturers, and sales people. 
This effort has received wholehearted support from the international 
community. The Asian National Cancer Center Alliance (ANCCA), the 
organization of National Cancer Centers in Asian countries, which was 
organized in September 2005 resolved to ban the manufacture and sale 
of tobacco products. Also, a meeting of National Cancer Institute Di-
rectors (organized at the International Agency for Research on Cancer 
(IARC) in October 2005) approved the Lyon Declaration which re-
solved to support every initiative to reduce the consumption of tobacco 
products in their countries, and ultimately to reach the complete ban on 
tobacco products.
There has been a widespread recognition on negative effects of smok-
ing in Korea within a relatively short period of time. In Korea, smokers 
were 79.3% of men and 12.5% of women in 1980 and this decreased to 
64.4 % of men and 5.5% of woman in 1996. After raising the price of 
tobacco, smoking prevalence was decreased to 44.1% of men, 2.9% of 
women in 2006. It is hoped that a further decrease in smoking preva-
lence will occur when the act on banning the manufacture and sale of 
tobacco products is enforced. However, it should be emphasized that 
this strategy of reducing tobacco consumption may not achieve its goal 
without international cooperation for tobacco control. 
Because over one billion adults and children are currently addicted 
to toxic tobacco products worldwide, there is no justiﬁable reason to 
permit this industry to continue making, marketing and distributing its 
products as if they were soft drinks. The ultimate goal for the Frame-
work Convention on Tobacco Control should be prohibiting corpora-
tions in the signatory nations from making, marketing and importing all 
tobacco products
We have to continue forming the broad worldwide network for banning 
tobacco, and comprehensive and determined activities of the network 
is achieving positive changes at the local, national, and international 
levels. We will continue to move the Tobacco-free World. 
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The history of this project has been covered in an abstract submitted 
for Educational session 5 and published in the Journal of Thoracic 
Oncology [1]. Additional abstracts in Educational session 5 submitted 
by other speakers will have covered several, additional aspects of the 
project. This abstract will focus upon the recommendations for TNM 
subsets and the stage groupings proposed in our submission to the 
UICC and AJCC. The talk will cover wider aspects of the project, as 
time allows.
The recommendations of the T, N and M descriptors sub-committees 
[2-4], the validation process [5] and the recommendation for the TNM 
subsets and stage groupings [6] will have been published in the Journal 
of Thoracic Oncology prior to the conference
In brief, the recommendations of the T descriptors sub-committee were: 
Subclassify:
• T1 as
 - T1a ( ≤ 2 cm) or
 - T1b (> 2 cm to ≤ 3 cm); and
• T2 as 
 - T2a (>3 to ≤ 5 cm or T2 by other factor and ≤ 5 cm) or
 -  T2b (>5 to ≤ 7 cm).
• Reclassify T2 tumours > 7 cm as T3.
• Reclassify T4 tumours by additional nodule/s in the lung (primary 
lobe) as T3.
• Reclassify M1 by additional nodule/s in the ipsilateral lung (differ-
ent lobe) as T4.
• Reclassify pleural dissemination (malignant pleural or pericardial 
effusions, pleural nodules) as M1.
The recommendations of the N descriptors sub-committee were that the 
existing N descriptors used in the 6th edition of the TNM classiﬁcation 
of lung cancer did not require changes or clariﬁcation.
The recommendations of the M descriptors sub-committee were:
• Reclassify pleural dissemination (malignant pleural effusions, pleu-
ral nodules) from T4 to M1a. 
• Subclassify M1 by additional nodules in the contralateral lung as 
M1a.
• Subclassify M1 by distant metastases (outside the lung/pleura) as 
M1b.
The proposed changes are as follows: 
• Incorporate proposed changes to T and M (affects T2,T3,T4 and M1 
categories). 
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• Reclassify T2aN1 tumours (≤5 cm) as stage IIA (from IIB). 
• Reclassify T2bN0 tumours (>5-7 cm) as stage IIA (from IB). 
• Reclassify T4N0 and T4N1 tumours as stage IIIA (from IIIB). 
The resultant TNM stage groupings are summarised as: 
Occult carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA T1a, b N0 M0
Stage IB T2a N0 M0
Stage IIA T1a, b N1 M0
T2a N1 M0
T2b N0 M0
Stage IIB T2b N1 M0
T3 N0 M0
Stage IIIA T1, T2 N2 M0
T3 N1, N2 M0
T4 N0, N1 M0
Stage IIIB T4 N2 M0
Any T N3 M0
Stage IV Any T Any N M1a,b
The table below summarises the descriptors, proposed T and M catego-
ries, and proposed stage groupings. Shaded cells indicate a proposed 
change from the 6th Edition of the TNM Classiﬁcation for lung cancer 
for a particular TNM category.




N0 N1 N2 N3
T1 (<=2cm) T1a IA IIA IIIA IIIB
T1 (>2 – 3 cm) T1b IA IIA IIIA IIIB
T2(<=5cm) T2a IB IIA IIIA IIIB
T2 (>5-7cm) T2b IIA IIB IIIA IIIB
T2 (>7cm) T3 IIB IIIA IIIA IIIB
T3 invasion IIB IIIA IIIA IIIB
T4 (same lobe nodules) IIB IIIA IIIA IIIB
T4 (extension) T4 IIIA IIIA IIIB IIIB
M1 (ipsilateral lung) IIIA IIIA IIIB IIIB
T4 (pleural eﬀusion) M1a IV IV IV IV
M1 (contralateral lung) IV IV IV IV
M1 (distant) M1b IV IV IV IV
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Current staging methods are inadequate for predicting outcome of 
treatment of lung cancer. Although, the need for better staging systems 
seems more relevant for early stage disease, improvements in treatment 
results also for advanced disease calls for a better staging/prognostic 
system.
The ability to deﬁne cancer subtypes, recurrence of disease and re-
sponse to speciﬁc therapies using DNA microarray-based gene expres-
sion signatures has been demonstrated in multiple studies (1) 
1. Early Stage NSCLC; Within the last years emerging data has justi-
ﬁed adjuvant therapy for subsets of early stage disease. Clinical studies 
have not yet justiﬁed the role of adjuvant therapy for stage IA. How-
ever, still about 25% of the NSCLC patients in stage IA will later have 
disease recurrence, which emphasize the importance of a better staging 
system. More recently several studies based on molecular markers have 
been published indicating the possibility of a more reﬁned classiﬁca-
tion of NSCLC patients with different outcome after surgery. In a study 
high risk stage I lung adenocarcinomas of Beer et al (2), it was possible 
to make a gene-risk proﬁling based on oligonucleotide array deﬁn-
ing clusters of genes with good and poor outcome. A kind of similar 
approach was taken by Potti et al. (3) in the lung metagene model. The 
lung metagene model predictited recurrence for individual patients 
signiﬁcantly better than did clinical prognostic factors and was con-
sistent across all early stages of NSCLC.The predictor also identiﬁed 
a subgroup of patients with stage IA disease who were at high risk for 
recurrence and who might be best treated with adjuvant chemotherapy. 
The metagene predictor is currently validated in a prospective CALGB 
study. Bild et al.(4) demonstrated that by identifying patterns of several 
pathway deregulation by using hierarchical clustering, it is possible to 
identify populations of patients with different prognosis. Independent 
of tumor histopathology concerted deregulation of Ras with β-catenin, 
Src and myc identiﬁed a group of lung cancer patients with poor sur-
vival with a median survival of 19.7 months versus 51.3 months for all 
other clusters (4). This analysis demonstrated the ability of integrated 
pathway analysis, based on multiple signatures of component pathway 
deregulation, to deﬁne improved categorization of lung cancer patients.
Other studies have used PCR based analysis in order to ﬁnd a better 
molecular prognostic signature. In a study from Taiwan a ﬁve-gene 
signature identiﬁed from 125 randomly selected patients who had 
undergone surgical resection of NSCLC, and the model were validated 
